Rosario will be part of a study that seeks to develop a new flu vaccine. For this reason, the Fundación Estudios Clínicos, which is part of an international team, invites adults over 65 years of age who have not been inoculated this year to participate in the clinical trial where the best tetravalent vaccine available on the market and the mRNA against the flu being studied.
The analysis is phase III, without the possibility of receiving a placebo (all participants will receive a flu vaccine), without cost and entails monitoring for six months of any type of infectious event of the respiratory tree.
Also read: How to differentiate flu symptoms from dengue fever
The project will be carried out at the Foundation’s headquarters (Italia 428) and is directed by Tomás Alvarez, pulmonologist and head of the entity’s Immunization area, together with a great team of medical researchers that accompany the entire development of the study.
For registration, those interested can enter www.vacunagripe.com or contact by phone or WhatsApp at 341-5-060005. More information in http://www.bastadegripe.com.
Year after year campaigns are carried out in the pre-winter stages for the prevention of flu infection, but: What is the flu? Why is prevention so important? The cold begins and with it the circulation of viruses, such as the flu, an infection of the airways.
effects
The flu generates between 3 and 5 million serious infections worldwide, and between 290,000 and 650,000 deaths; It is also one of the main causes of work and school absenteeism.
The flu virus has changes in its composition as it multiplies, and this causes it to mutate over time, which is why you don’t have the same types of influenza every year.
Among the unsatisfied needs that science tries to overcome is the growing need to prevent these infections, especially the severe ones, which usually affect vulnerable people, such as those under 2 years of age or over 65, and all those with chronic diseases. moderate or severe, since they are considered high risk.
on the rise
In 2022, the incidence of influenza grew by 21 percent compared to the 2019 record, developing 3 viral circulation peaks in the year. This continuous increase causes annual epidemics and occasionally pandemics.
Faced with this reality, there are vaccines, some included in vaccination campaigns and others only accessible in the private sphere, which have a level of immunogenicity that rarely reaches 60 percent.
For this reason, the research area is looking for a way to improve this immunogenic capacity, and the new technologies based on mRNA (or also known as messenger RNA vaccines) are the strategies that are showing the best results in this regard.
The current experience with the mRNA vaccines available for Covid demonstrated a coverage greater than 90 percent that laid the foundations for the development of these new vaccines with the aim of covering other diseases such as influenza.
